Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-C in rat models

Figure 4 Effect of plecanatide and dolcanatide on localization of ZO-1 in epithelial cells Caco-2 (A) and T84 (B) cell monolayers were treated with 1 μmol/L plecanatide or dolcanatide in the presence of 100 μg/mL of LPS for 16 h followed by immunofluorescence imaging for ZO-1. Representative microscopic fields depicted above demonstrate disruption of ZO-1 localization by LPS. In Caco-2 cells, LPS treatment appears to cause accumulation of ZO-1 in the cytoplasm. Co-treatment of LPS with plecanatide or dolcanatide preserved ZO-1 localization around the cell membrane as observed for vehicle treated cells. Images taken at 40× resolution. Blue fluorescence corresponds to DAPI stained nucleus. DAPI: 4’, 6’-Diamidino-2-phenylindole; LPS: Lipopolysaccharide; ZO-1: Zonula occludens-1.